INPEFA (sotagliflozin)

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals leverages its unique target discovery platform, which systematically analyzes gene function, to identify and validate novel drug targets for therapeutic development. The company achieved a significant milestone with the FDA approval of INPEFA® (sotagliflozin) for reducing cardiovascular death and hospitalization in heart failure patients. Its strategy focuses on advancing its commercial product and progressing its pipeline of internally discovered drug candidates in areas of high unmet medical need, including cardiometabolic and neuropathic disorders.

Therapeutic Areas

Other Heart Failure Drugs